#United States #New York #Class Action #Securities Fraud #Capricor Therapeutics

Capricor Therapeutics Class Action Overview

Capricor Therapeutics, Inc. has become the subject of a class action lawsuit aimed at compensating shareholders affected by alleged securities fraud. Investors are alerted by Levi & Korsinsky, LLP about the lawsuit's timeline, with an important deadline approaching on September 15, 2025, for those wishing to be appointed lead plaintiffs. This article details the significant aspects of the case, how investors can respond, and potential implications for shareholders.

Background of the Case

The lawsuit targets Capricor's management during a period when they made several optimistic projections regarding their lead drug candidate, deramiocel, intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Notably, the complaint indicates that the company's executives presented glowing remarks about their progress towards a Biologics License Application (BLA) from the U.S. FDA, while allegedly concealing critical information from investors.

In particular, statements made by Capricor included claims of the drug’s effectiveness, which were later challenged by data from the Phase 2 HOPE-2 trial. On July 11, 2025, following a series of concerning press releases, the FDA issued a Complete Response Letter (CRL) to Capricor, declaring that their application did not meet the required standards and pointing out the absence of sufficient evidence regarding the drug’s effectiveness.

This announcement had an immediate effect, leading to a stock price drop for Capricor, plummeting from $11.40 per share to $7.64 in just a day. Such a decline reflects a significant loss for investors who trusted the prior affirmations made by the company.

Class Action Details

The ongoing class action seeks to secure financial restitution for those who held shares in Capricor during the defined period of October 9, 2024, through July 10, 2025. Investors potentially impacted are encouraged to review their eligibility to partake in the lawsuit, as membership in the class can help recover losses resulting from the alleged fraudulent activities. It’s important to note that even if an investor does not wish to act as a lead plaintiff, they may still qualify for compensation.

How Investors Can Get Involved

For those who suffered losses, the process to join the class action is straightforward. Interested investors have until the deadline of September 15, 2025, to apply for lead plaintiff status. This is an opportunity for shareholders to stand up against alleged misconduct within the company. Levi & Korsinsky emphasizes that engaging in this legal action carries no out-of-pocket costs for class members, making it a viable option for those affected.

To learn more about how to join the lawsuit, potential plaintiffs can visit the official link provided by Levi & Korsinsky or reach out directly to the firm via email or phone. Detailed information will be provided, and legal professionals will be available to assist investors through the process.

The Importance of Legal Representation

Levi & Korsinsky have established a strong reputation in securities litigation, having secured substantial sums for investors in similar cases over the last two decades. Their experienced team specializes in complex securities issues and is well-equipped to navigate this type of litigation.

With a workforce of over 70 employees dedicated to client service, they offer a level of commitment and expertise that benefits investors looking for resolution in their legal matters.

The proactive steps investors take now could significantly impact their potential recovery as the class action moves forward. With the looming deadline of September 15, those with stakes in Capricor Therapeutics are urged to act promptly to ensure their interests are represented.

In summary, as the legal proceedings unfold, Capricor’s investors should be informed and actively engaged, thereby maximizing the possibility for a financial recovering amid challenging circumstances.

For further inquiries regarding the class-action details, contact Levi & Korsinsky at their New York office. Their commitment to defending investor rights provides a solid backing for those who have faced financial adversity from their association with Capricor Therapeutics.

Conclusion

Capricor Therapeutics finds itself at a critical juncture as it faces serious allegations of securities fraud. This serves as a reminder for investors to remain vigilant and informed about the companies they invest in, and to act swiftly to protect their financial interests when necessary. The class action lawsuit offers a platform for voicing grievances and potentially reclaiming lost investments.

Contact Information

To further explore your options regarding the Capricor lawsuit, reach out to Levi & Korsinsky at: 33 Whitehall Street, 17th Floor, New York, NY 10004 or call (212) 363-7500.